<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Obstetrics and Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics and Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство и гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0300-9092</issn><issn publication-format="electronic">2412-5679</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">332814</article-id><article-id pub-id-type="doi">10.18565/aig.2022.269</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Обзоры</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Feasibility of predicting fetal growth restriction, by identifying plasma biomarkers</article-title><trans-title-group xml:lang="ru"><trans-title>Возможность прогнозирования задержки роста плода на основе определения биомаркеров в плазме крови</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Izhoykina</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Ижойкина</surname><given-names>Екатерина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Laboratory Assistant, Department of Obstetrics and Gynecology</p></bio><bio xml:lang="ru"><p>лаборант кафедры акушерства и гинекологии</p></bio><email>katushkabig@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Trifonova</surname><given-names>Ekaterina A.</given-names></name><name xml:lang="ru"><surname>Трифонова</surname><given-names>Екатерина Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Senior Researcher, Research Institute of Medical Genetics</p></bio><bio xml:lang="ru"><p>к.м.н., с.н.с., НИИ медицинской генетики</p></bio><email>ekaterina.trifonova@medgenetics.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kutsenko</surname><given-names>Irina G.</given-names></name><name xml:lang="ru"><surname>Куценко</surname><given-names>Ирина Георгиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, заведующая кафедрой акушерства и гинекологии</p></bio><email>kutsenko.ig@ssmu.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stepanov</surname><given-names>Igor A.</given-names></name><name xml:lang="ru"><surname>Степанов</surname><given-names>Игорь Ардалионович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Chief Physician</p></bio><bio xml:lang="ru"><p>к.м.н., главный врач</p></bio><email>StepanovIA@opc.tomsk.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Gavrilenko</surname><given-names>Maria M.</given-names></name><name xml:lang="ru"><surname>Гавриленко</surname><given-names>Мария Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Ph.D. student, Research Institute of Medical Genetics</p></bio><bio xml:lang="ru"><p>аспирант, НИИ медицинской генетики</p></bio><email>maria.gavrilenko@medgenetics.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stepanov</surname><given-names>Vadim A.</given-names></name><name xml:lang="ru"><surname>Степанов</surname><given-names>Вадим Анатольевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Academician of RAS, Dr. Bio. Sci., Professor, Director of the Research Institute of Medical Genetics</p></bio><bio xml:lang="ru"><p>академик РАН, д.б.н., профессор, директор НИИ медицинской генетики</p></bio><email>vadim.stepanov@medgenetics.ru</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Siberian State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.D. Evtushenko Regional Perinatal Center</institution></aff><aff><institution xml:lang="ru">ОГАУЗ «Областной перинатальный центр имени И.Д. Евтушенко»</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Tomsk National Research Medical Center, Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-04-18" publication-format="electronic"><day>18</day><month>04</month><year>2023</year></pub-date><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>18</fpage><lpage>24</lpage><history><date date-type="received" iso-8601-date="2023-04-15"><day>15</day><month>04</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-04-15"><day>15</day><month>04</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО «Бионика Медиа»</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/0300-9092/article/view/332814">https://journals.eco-vector.com/0300-9092/article/view/332814</self-uri><abstract xml:lang="en"><p><italic>Fetal growth restriction (FGR) remains one of the important obstetric problems, being a risk factor for antenatal and neonatal mortality and morbidity. The timely prediction of FGR is one of the most important measures in reducing adverse pregnancy outcomes. However, despite numerous studies, practical obstetrics still lacks highly sensitive and specific prognostic biomarkers for this disease.</italic></p> <p><italic>This paper analyzes open-access modern scientific literature data in the PubMed, Cochrane, and eLibrary databases, which characterize the role of biomarkers in predicting the risk of FGR. Meta-analyses demonstrate that beta-human chorionic gonadotropin, alpha-fetoprotein, free estriol, human chorionic somatomammotropin hormone 1, pappalysin 1, inhibin </italic><italic>α</italic><italic>-subunit, and placental growth factor are considered the most promising predictive biomarkers for FGR. However, the data obtained by most authors suggest that the use of individual biomarkers has insufficient sensitivity and specificity in stratifying the risk of FGR. The most promising direction in this area is the creation of models for complex multiparametric screening based on the study of maternal risk factors, the levels of biomarkers (both proteomic and molecular genetic ones) in conjunction with ultrasound data.</italic></p> <p><bold><italic>Conclusion:</italic></bold><italic> Thus, studies focused on the search for new biomarkers in order to develop a comprehensive screening program that is of high prognostic value in identifying the risk of FGR are highly relevant and determine personalized patient management tactics in the future.</italic></p></abstract><trans-abstract xml:lang="ru"><p><italic>Задержка роста плода (ЗРП) остается одной из важных проблем акушерства, являясь фактором риска антенатальной и неонатальной смертности и заболеваемости. Своевременное прогнозирование ЗРП – одно из важнейших мероприятий в снижении неблагоприятных исходов беременности. Однако, несмотря на многочисленные исследования, практическое акушерство по-прежнему не имеет высокочувствительных и специфичных прогностических биомаркеров данного заболевания.</italic></p> <p><italic>В рамках представленной статьи проведен анализ современных литературных данных в базах PubMed, Cochrane, eLibrary, опубликованных в открытом доступе и характеризующих роль биомаркеров в прогнозировании риска развития ЗРП. В качестве наиболее перспективных предиктивных биомаркеров ЗРП, по данным метаанализов, рассматриваются β-хорионический гонадотропин человека (β-HCG), α-фетопротеин (AFP), свободный эстриол (Е3), хорионический соматомаммотропный гормон 1 (CSH), паппализин 1 (РАРР-А), α-субъединица ингибина (Inhibin-А) и плацентарный фактор роста (PIGF). Однако данные, полученные большинством авторов, свидетельствуют о том, что использование отдельных биомаркеров обладает недостаточной чувствительностью и специфичностью в стратификации риска развития ЗРП. Наиболее перспективным направлением в этой области является разработка моделей комплексного мультипараметрического скрининга, основанного на изучении материнских факторов риска, уровней биомаркеров (как протеомных, так и молекулярно-генетических) в совокупности с данными ультразвукового исследования.</italic></p> <p><bold><italic>Заключение:</italic></bold><italic> Таким образом, исследования, сфокусированные на поиске новых биомаркеров с целью разработки комплексной скрининговой программы, обладающей высокой прогностической значимостью в выявлении риска развития ЗРП, являются высокоактуальными и определяют персонифицированную тактику ведения пациентки в будущем.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>fetal growth restriction</kwd><kwd>biomarkers</kwd><kwd>screening</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>задержка роста плода</kwd><kwd>биомаркеры</kwd><kwd>скрининг</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Russian Society of Obstetricians and Gynecologists. Clinical guidelines “Inadequate fetal growth requiring maternal medical care (fetal growth restriction)”. 2020. (in Russian)</mixed-citation><mixed-citation xml:lang="ru">Российское общество акушеров-гинекологов. Клинические рекомендации «Недостаточный рост плода, требующий предоставления медицинской помощи матери (задержка роста плода)». 2020.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><mixed-citation>Heazell A.E., Hayes D.Jl., Whitworth M., Takwoingi Y., Bayliss S.E., Davenport C. Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants. Cochrane Database Syst. Rev. 2019; 5(5): CD012245. https://dx.doi.org/10.1002/ 14651858.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Levine T.A, Grunau R.E., McAuliffe F.M., Pinnamaneni R.M., Foran A., Alderdice F.A. Early childhood neurodevelopment after intrauterine growth restriction: a systematic review. Pediatrics. 2015; 135(1): 126-41. https://dx.doi.org/10.1542/peds.2014-1143.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Colella M., Frérot A., Novais A.R.B., Baud O. Neonatal and long-term consequences of fetal growth restriction. Curr. Pediatr. Rev. 2018; 14(4): 212-8. https://dx.doi.org/10.2174/1573396314666180712114531.</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Khachatryan Z.V., Kan N.E., Makarova N.P. Present views on molecular mechanisms of formation of fetal growth restriction. Obstetrics and Gynecology. 2019; (10): 22-6. (in Russian). https://dx.doi.org/10.18565/aig.2019.10.22-26.</mixed-citation><mixed-citation xml:lang="ru">Хачатрян З.В., Кан Н.Е., Макарова Н.П. Современные представления о молекулярных механизмах формирования задержки роста плода. Акушерство и гинекология. 2019; 10: 22-6. https://dx.doi.org/10.18565/aig.2019.10.22-26. https://dx.doi.org/10.18565/aig.2019.10.22-26.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Burton G.J., Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am. J. Obstet. Gynecol. 2018; 218(Suppl. 2): S745-61. https://dx.doi.org/10.1016/j.ajog.2017.11.577.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Zur R.L., Kingdom J.C., Parks W.T., Hobson S.R. The placental basis of fetal growth restriction. Obstet. Gynecol. Clin. North Am. 2020; 47(1): 81-98. https://dx.doi.org/10.1016/j.ogc.2019.10.008.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zareaan E., Heidarpour M., Kargarzadeh E., Moshfeghi M. Association of maternal and umbilical cord blood leptin concentrations and abnormal color Doppler indices of umbilical artery with fetal growth restriction. Int. J. Reprod. Biomed. 2017; 15(3): 135-40.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ferrero S., Mazarico E., Valls C., Di Gregorio S., Montejo R., Ibáñez L. et al. Relationship between fetal growth restriction and maternal nutrition status measured by Dual-Energy X-Ray absorptiometry, leptin, and insulin-like growth factor. Gynecol. Obstet. Invest. 2015; 80(1): 54-9. https://dx.doi.org/10.1159/000371761.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Visentin S., Lapolla A., Londero A.P., Cosma C., Dalfrà M., Camerin M. et al. Adiponectin levels are reduced while markers of systemic inflammation and aortic remodelling are increased in intrauterine growth restricted mother-child couple. Biomed. Res. Int. 2014; 2014: 401595. https://dx.doi.org/10.1155/2014/ 401595.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Madeleneau D., Buffat C., Mondon F., Grimault H., Rigourd V., Tsatsaris V. et al. Transcriptomic analysis of human placenta in intrauterine growth restriction. Pediatr. Res. 2015; 77(6): 799-807. https://dx.doi.org/10.1038/ pr.2015.40.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Zhang C., Ding J., Li H., Wang T. Identification of key genes in pathogenesis of placental insufficiency intrauterine growth restriction. BMC Pregnancy Childbirth. 2022; 22(1): 77. https://dx.doi.org/10.1186/s12884-022-04399-3.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Cignini P., Savasta L.M., Gulino F.A., Vitale S.G., Mangiafico L., Mesoraca A., Giorlandino C. Predictive value of pregnancy-associated plasma protein-A (PAPP-A) and free beta-hCG on fetal growth restriction: results of a prospective study. Arch. Gynecol. Obstet. 2016; 293(6): 1227-33. https://dx.doi.org/10.1007/s00404-015-3947-z.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Boonpiam R., Wanapirak C., Sirichotiyakul S., Sekararithi R., Traisrisilp K., Tongsong T. Quad test for fetal aneuploidy screening as a predictor of small-for-gestational age fetuses: a population-based study. BMC Pregnancy Childbirth. 2020; 20(1): 621. https://dx.doi.org/10.1186/s12884-020-03298-9.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Kiyokoba R., Uchiumi T., Yagi M., Toshima T., Tsukahara S., Fujita Y. et al. Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction. Sci. Rep. 2022; 12(1): 4056. https://dx.doi.org/10.1038/s41598-022-07893-y.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Yu N., Cui H., Chen X., Chang Y. First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction. Taiwan. J. Obstet. Gynecol. 2017; 56(3): 358-61. https://dx.doi.org/10.1016/j.tjog.2017.01.009.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Zamarian A.C.P., Araujo E.Jn., Daher S., Rolo L.C., Moron A.F., Nardozza L.M.M. Evaluation of biochemical markers combined with uterine artery Doppler parameters in fetuses with growth restriction: a case-control study. Arch. Gynecol. Obstet. 2016; 294(4): 715-23. https://dx.doi.org/10.1007/ s00404-016-4024-y.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Sifakis S., Androutsopoulos V.P., Pontikaki A., Velegrakis A., Papaioannou G.I., Koukoura O. et al. Placental expression of PAPPA, PAPPA-2 and PLAC-1 in pregnacies is associated with FGR. Mol. Med. Rep. 2018; 17(5): 6435-40. https://dx.doi.org/10.3892/mmr.2018.8721.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Yazdani S., Rouholahnejad R., Asnafi N., Sharbatdaran M., Zakershob M., Bouzari Z. Correlation of pregnancy outcome with quadruple screening test at second trimester. Med. J. Islam. Repub. Iran. 2015; 29: 281.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Awamleh Z., Gloor G.B., Han V.K.M. Placental microRNAs in pregnancies with early onset intrauterine growth restriction and preeclampsia: potential impact on gene expression and pathophysiology. BMC Med. Genomics. 2019; 12: 91. https://dx.doi.org/10.1186/s12920-019-0548-x.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Nawathe A.R., Christian M., Kim S.H., Johnson M., Savvidou M.D., Terzidou V. Insulin-like growth factor axis in pregnancies affected by fetal growth disorders. Clin. Epigenetics. 2016; 8: 11. https://dx.doi.org/10.1186/s13148-016-0178-5.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Lesmes C., Gallo D.M., Gonzalez R., Poon L.C., Nicolaides K.H. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19-24 weeks. Ultrasound Obstet. Gynecol. 2015; 46(3): 341-9. https://dx.doi.org/10.1002/uog.14899.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Komwilaisak R., Tangkiratichai P. Maternal serum angiogenic growth factors in intrauterine growth restriction versus normal pregnancies. J. Med. Assoc. Thai. 2017; 100(2): 119-24.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Ravikumar G., Mukhopadhyay A., Mani C., Kocchar P., Crasta J., Thomas T. et al. Placental expression of angiogenesis-related genes and their receptors in IUGR pregnancies: correlation with fetoplacental and maternal parameters. J. Matern. Fetal Neonatal Med. 2019; 28: 1-8. https://dx.doi.org/10.1080/ 14767058.2019.1593362.</mixed-citation></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Khachatryan Z.V., Kan N.E., Vtorushina V.V., Krechetova L.V., Kharchenko D.K., Mantrova D.A., Tyutyunnik V.L. Role of transforming growth factor-β in the formation of fetal growth restriction. Obstetrics and Gynecology. 2019; (11): 107-12. (in Russian). https://dx.doi.org/10.18565/aig.2019.11.107-112.</mixed-citation><mixed-citation xml:lang="ru">Хачатрян З.В., Кан Н.Е., Вторушина В.В., Кречетова Л.В., Харченко Д.К., Мантрова Д.А., Тютюнник В.Л. Роль трансформирующего фактора роста β в формировании задержки роста плода Акушерство и гинекология. 2019; 11: 107-12. https://dx.doi.org/10.18565/aig.2019.11.107-112.</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Krasnyi A.M., Khachaturyan A.A., Vtorushina V.V., Krechetova L.V., Kan N.E., Tyutyunnik V.L. Plasma levels of soluble E-cadherin and the keratinocytes growth factor in intrauterine growth restriction. Obstetrics and Gynecology. 2020; (6): 37-42. (in Russian). https://dx.doi.org/10.18565/aig.2020.6.37-42.</mixed-citation><mixed-citation xml:lang="ru">Красный А.М., Хачатурян А.А., Вторушина В.В., Кречетова Л.В., Кан Н.Е., Тютюнник В.Л. Содержание растворимой формы Е-кадгерина и фактора роста кератиноцитов в плазме крови при задержке роста плода. Акушерство и гинекология. 2020; 6: 37-42. https://dx.doi.org/10.18565/aig.2020.6.37-42.</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><mixed-citation>Raia-Barjat T., Prieux C., Gris J-C., Chapelle C., Laporte S., Chauleur C. Angiogenic factors for prediction of preeclampsia and intrauterine growth restriction onset in high-risk women: AngioPred study. J. Matern. Fetal Neonatal Med. 2019; 32(2): 248-57. https://dx.doi.org/ 10.1080/14767058.2017.1378325.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Şahin B., Soyer-Çalışkan C., Çelik S., Hatırnaz Ş., Tinelli A. Midregional pro-adrenomedullin and matrix metalloproteinase-2 levels in intrauterine growth restriction and small gestational age pregnancies: biochemical diagnostic difference. J. Matern. Fetal Neonatal Med. 2021; 34(12): 1999-2005. https://dx.doi.org/10.1080/14767058.2020.1846707.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ibrahim M.I., Ammar E.M., Ramy A., Ellaithy M.I., Abdelrahman R.M., Elkabarity R. The association between pentraxin 3 in maternal circulation and pathological intrauterine fetal growth restriction. Eur. J. Obstet. Gynecol. Reprod. Biol. 2015; 185: 1-8. https://dx.doi.org/10.1016/ j.ejogrb.2014.11.010.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Andres F., Wong G.P., Walker S.P., MacDonald T.M., Keenan E., Cannon P. et al. A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeks' gestation in pregnancies destined to deliver small for gestational age infants. Placenta. 2022; 117: 1-4. https://dx.doi.org/10.1016/j.placenta.2021.11.001.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Docheva N., Romero R., Chaemsaithong P., Tarca A.L., Bhatti G., Pacora P. et al. The profiles of soluble adhesion molecules in the "great obstetrical syndromes". J. Matern. Fetal Neonatal Med. 2019; 32(13): 2113-36. https://dx.doi.org/ 10.1080/14767058.2018.1427058.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Berbets A., Koval H., Barbe A., Albota O., Yuzko O. Melatonin decreases and cytokines increase in women with placental insufficiency. J. Matern. Fetal Neonatal Med. 2021; 34(3): 373-8. https://dx.doi.org/10.1080/ 14767058.2019.1608432.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Medina-Bastidas D., Guzmán-Huerta M., Borboa-Olivares H., Ruiz-Cruz C., Parra-Hernández S., Flores-Pliego A. et al. Placental microarray profiling reveals common mRNA and lncRNA expression patterns in preeclampsia and intrauterine growth restriction Int. J. Mol. Sci. 2020; 21(10): 3597. https://dx.doi.org/10.3390/ijms21103597.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Azizieh F.Y., Raghupathy R.G. Tumor necrosis factor-α and pregnancy complications: a prospective study. Med. Princ. Pract. 2015; 24(2): 165-70. https://dx.doi.org/10.1159/000369363.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Karlı P., Özdemir A.Z., Ayan D. Maternal serum and fetal cord blood C-reactive protein levels but not procalcitonin levels are increased in idiopathic intrauterine gowth restriction. Med. Sci. Monit. 2019; 25: 6512-7. https://dx.doi.org/10.12659/MSM.917397.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Dai F.F., Hu M., Zhang Y.W., Zhu R.H., Chen L.P., Li Z.D. et al. Maternal serum and fetal cord blood C-reactive protein levels but not procalcitonin levels are increased in idiopathic intrauterine gowth restriction. Expert Rev. Mol. Med. 2022; 24: e26. https://dx.doi.org/10.1017/ erm.2022.18.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Pylypjuk C.L., Monarrez-Espino J. False-positive maternal serum screens in the second trimester as markers of placentally mediated complications later in pregnancy: a systematic review and meta-analysis. Dis. Markers. 2021; 2021: 5566234. https://dx.doi.org/10.1155/2021/5566234.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Heazell A.E.P., Whitworth M., Duley L., Thornton J.G. Use of biochemical tests of placental function for improving pregnancy outcome. Cochrane Database Syst. Rev. 2015; 2015(11): CD011202. https://dx.doi.org/10.1002/ 14651858.CD011202.pub2.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Morris R.K., Bilagi A., Devani P., Kilby M.D. Association of serum PAPP-A levels in first trimester with small for gestational age and adverse pregnancy outcomes: systematic review and meta-analysis. Prenat. Diagn. 2017; 37(3): 253-65. https://dx.doi.org/10.1002/pd.5001.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Chen W., Wei Q., Liang Q., Song S., Li J. Diagnostic capacity of sFlt-1/PlGF ratio in fetal growth restriction: a systematic review and meta-analysis. Placenta. 2022; 127: 37-42. https://dx.doi.org/10.1016/j.placenta.2022.07.020.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Kiyokoba R., Uchiumi T., Yagi M., Toshima Т., Tsukahara S., Fujita Y. et al. Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction. Sci. Rep. 2022; 12: 4056.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Costa M.A. The endocrine function of human placenta: an overview. Reprod. Biomed. Online. 2016; 32(1): 14-43. https://dx.doi.org/10.1016/ j.rbmo.2015.10.005.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Yu N., Cui H., Chen X., Chang Y. First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction. Taiwan. J. Obstet. Gynecol. 2017; 56(3): 358-61. https://dx.doi.org/10.1016/j.tjog.2017.01.009.</mixed-citation></ref></ref-list></back></article>
